Results 91 to 100 of about 106,545 (283)

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Indian Journal of Medical and Paediatric Oncology, 2017
Introduction: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP)
Puligundla Krishna Chaitanya, Karnam Ashok Kumar, Bala Stalin, Gundeti Sadashivudu, Maddali Lakshmi Srinivas   +4 more
doaj   +1 more source

Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. [PDF]

PLoS ONE, 2010
The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure.
Jiye A, Sixuan Qian, Guangji Wang, Bei Yan, Sujiang Zhang, Qing Huang, Lingna Ni, Weibin Zha, Linsheng Liu, Bei Cao, Ming Hong, Hanxin Wu, Hua Lu, Jian Shi, Mengjie Li, Jianyong Li   +15 more
doaj   +1 more source

National Institute for Clinical Excellence and its value judgments [PDF]

, 2004
The National Institute for Clinical Excellence (NICE) offers health professionals in England and Wales advice on providing NHS patients with the highest attainable standards of care.
Culyer, A.J., Rawlins, M.D.
core   +2 more sources

A Comprehensive Review on Capillary Electrophoresis–Mass Spectrometry in Advancing Biomolecular Research

ELECTROPHORESIS, EarlyView.
ABSTRACT This review provides an in‐depth exploration of capillary electrophoresis–mass spectrometry (CE–MS) in biomolecular research from 2020 to 2024. CE–MS emerges as a versatile and powerful tool due to its numerous advantages, facilitating the analysis of various biomolecules, including proteins, peptides, oligonucleotides, and other metabolites ...
Laura Pont, María Vergara‐Barberán, Enrique Javier Carrasco‐Correa   +2 more
wiley   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Watching the Barn Door Open—Timing CML Stem Cell Allografts

American Journal of Hematology, EarlyView.
Jeffrey H. Lipton
wiley   +1 more source

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

Head &Neck, EarlyView.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after ...
Tomomi Sanomachi, Tatsunori Shimoi, Yuki Kojima, Hideaki Takahashi, Motoko Arakaki, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Aiko Maejima, Tadaaki Nishikawa, Kazuki Sudo, Taisuke Mori, Yasuhiro Fujiwara, Kan Yonemori   +16 more
wiley   +1 more source

Single-cell epigenomic variability reveals functional cancer heterogeneity. [PDF]

, 2017
BackgroundCell-to-cell heterogeneity is a major driver of cancer evolution, progression, and emergence of drug resistance. Epigenomic variation at the single-cell level can rapidly create cancer heterogeneity but is difficult to detect and assess ...
Buenrostro, Jason D, Chang, Howard Y, Greenleaf, William J, Kathiria, Arwa, Litzenburger, Ulrike M, Sheffield, Nathan C, Shen, Ying, Wu, Beijing   +7 more
core   +2 more sources

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database

American Journal of Hematology, EarlyView.
Fabio Stagno, Rosalba Cucci, Giovanni Marsili, Fausto Castagnetti, Sara Galimberti, Barbara Izzo, Federica Sorà, Simona Soverini, Monica Messina, Alfonso Piciocchi, Massimiliano Bonifacio, Daniela Cilloni, Alessandra Iurlo, Giovanni Martinelli, Gianantonio Rosti, Paola Fazi, Marco Vignetti, Massimo Breccia, Alessandro Allegra, Fabrizio Pane   +19 more
wiley   +1 more source

Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids

International Journal of Cancer, EarlyView.
What's New? Poor prognosis in cholangiocarcinoma (CCA) is attributed to late diagnosis and intrinsic chemoresistance. In particular, resistance mechanisms that suppress apoptosis limit the effectiveness of gemcitabine‐based regimens, which remain the standard treatment.
Wunan Mi, Gilles S. van Tienderen, Shaojun Shi, Amy Broeders, Kathryn Monfils, Henk P. Roest, Luc J. W. van der Laan, Monique M. A. Verstegen   +7 more
wiley   +1 more source